FDA Clears Ascletis ASC30 Phase II Diabetes Study
HONG KONG, Jan. 5, 2026 — Ascletis Pharma Inc. announced that it has received Investigational New Drug (IND) clearance...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
HONG KONG, Jan. 5, 2026 — Ascletis Pharma Inc. announced that it has received Investigational New Drug (IND) clearance...
